Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance
Alexander C. Huang, Roberta Zappasodi
Nature Immunology (2022) Vol. 23, Iss. 5, pp. 660-670
Open Access | Times Cited: 389

Showing 1-25 of 389 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 476
CD4+ T cells in cancer
Daniel E. Speiser, Obinna Chijioke, Karin Schaeuble, et al.
Nature Cancer (2023) Vol. 4, Iss. 3, pp. 317-329
Closed Access | Times Cited: 247
Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Haozhen Lv, Xiao Liu, Xuanhao Zeng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 184
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 136
Melanoma Management: From Epidemiology to Treatment and Latest Advances
Joana Lopes, Cecília M. P. Rodrigues, Maria Manuela Gaspar, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4652-4652
Open Access | Times Cited: 95
Multifunctional nanomedicines-enabled chemodynamic-synergized multimodal tumor therapy via Fenton and Fenton-like reactions
Haiyan Gao, Zhiping Cao, Huanhuan Liu, et al.
Theranostics (2023) Vol. 13, Iss. 6, pp. 1974-2014
Open Access | Times Cited: 66
Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
Feyza Gül Özbay Kurt, Samantha Lasser, Ihor Arkhypov, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 13
Open Access | Times Cited: 61
Photodynamic therapy combined with immunotherapy: Recent advances and future research directions
Marta Warszyńska, Paweł Repetowski, J. Dąbrowski
Coordination Chemistry Reviews (2023) Vol. 495, pp. 215350-215350
Open Access | Times Cited: 60
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 697-715
Closed Access | Times Cited: 54
Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo‐Immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment
Yunkun Li, Yahui Wu, Zaixiang Fang, et al.
Advanced Materials (2023) Vol. 36, Iss. 2
Closed Access | Times Cited: 46
Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma
Yantao Ding, Zhijie Zhao, Huabao Cai, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 46
Pairing of single-cell RNA analysis and T cell antigen receptor profiling indicates breakdown of T cell tolerance checkpoints in atherosclerosis
Zhihua Wang, Xi Zhang, Shu Lu, et al.
Nature Cardiovascular Research (2023) Vol. 2, Iss. 3, pp. 290-306
Open Access | Times Cited: 42
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy
Judith Wienke, Lindy L. Visser, Waleed M. Kholosy, et al.
Cancer Cell (2024)
Open Access | Times Cited: 35
The Integration of Clinical Trials With the Practice of Medicine
Derek C. Angus, Alison J. Huang, Roger Lewis, et al.
JAMA (2024) Vol. 332, Iss. 2, pp. 153-153
Closed Access | Times Cited: 23
Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment
Junyu Qiu, Zilin Cheng, Zheng Jiang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5490-5490
Open Access | Times Cited: 17
Regulatory T cells in immune checkpoint blockade antitumor therapy
An Zhang, Tao Fan, Yixiao Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 17
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy
Xinyue Shao, Xiaoling Zhao, Binghao Wang, et al.
Theranostics (2025) Vol. 15, Iss. 5, pp. 1689-1714
Open Access | Times Cited: 4
IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control
Béatrice Breart, Katherine Williams, Stellanie Krimm, et al.
Nature (2025)
Closed Access | Times Cited: 3
VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1
Zongfu Pan, Jinming Chen, Tong Xu, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 2
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 59
Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance
Jin Yan, Dan Liu, Jingmei Wang, et al.
Drug Resistance Updates (2023) Vol. 73, pp. 101037-101037
Open Access | Times Cited: 41
Tumor‐Specific Peroxynitrite Overproduction Disrupts Metabolic Homeostasis for Sensitizing Melanoma Immunotherapy
Lijun Yang, Dianyu Wang, Haixue Jia, et al.
Advanced Materials (2023) Vol. 35, Iss. 29
Closed Access | Times Cited: 36
Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy
Yue Wang, Shikun Zhou, Yan Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 32
Immunobiology of cholangiocarcinoma
Jennifer L. Tomlinson, Juan W. Valle, Sumera I. Ilyas
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 867-875
Open Access | Times Cited: 31
Light-responsive nanomedicine for cancer immunotherapy
Weirong Kang, Yuwei Liu, Weiping Wang
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2346-2368
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top